For example, whether targeted therapy can be integrated into the regimen for MPMNs with actionable mutations (e.g., EGFR mutations in lung cancer (21), BRCA mutations in ovarian cancer (22)) requires further investigation. The gene discussed is EGFR; the disease is lung cancer.